A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product.

• Status: Unknown status
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Hyperuricemia is a common metabolic disorder.The Yaizu Suisankagaku Industry Company have developed industrial production named Marine Active, was able to offer anti-fatigue activity by animal trial data. Human clinical trials showed reduced creatine phosphokinase activity and a sero-uric acid reduction activity was also observed. So we are committed to design the clinical randomized, double blind study about hyperuricemia management with Marine Active. All these efforts are hoped to find a novel method to manage hyperuricemia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: China Medical University Hospital

Criteria

Inclusion Criteria:

• Male or female patients, age between 18 to 60 years

• With the data of serum uric acid level more than 8.0 mg/dl within 2 weeks before the initiation of study

• Signed informed consent obtained prior to inclusion into the study

Exclusion Criteria:

• Pregnant women.

• Acute onset of gouty arthritis or renal stone

• Significant liver or renal dysfunction, hematological disease, oncological disease, or other life threatens disorders.

• Condition that need the management of diuretics or analgesics agent

• Have been administrated by anti-hyperuricemia agent or healthy food with in 4 weeks before the initiation of study.

• The serum uric acid level could be decrease to lower than 8 mg/dl by diet control.